Inhaled PDE4 inhibition: CHF6001 (Tanimilast) is an inhaled PDE4 inhibitor currently in a phase 3 clinical trial for COPD patients with a history of exacerbations despite ongoing triple inhaled therapy (Table 2). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.